$1.90+4.1%Nov 13 close
Reported results on November 5, 2026; they are not in these figures yet.
Next earnings: November 19, 2026
Figures through June 30, 2026, from the 10-Q filed August 14, 2026
Processa Pharmaceuticals, Inc. is scheduled to report next on November 19, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending September 30, 2023, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2023 | 3 months toSep 30, 2022 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Processa Pharmaceuticals, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Pharmaceuticals, Inc. The mission of Processa is to develop the Next Generation Chemotherapies (with existing clinical evidence of safety and efficacy) for cancer patients who need better cancer drugs to extend survival and/or improve their quality of life. The Company uses its Regulatory Science Approach and the principles of the FDA’s Project Optimus Oncology initiative to provide an efficient development program, increase the probability of approval, and provide a safer and better cancer treatment that can be easily differentiated from what is presently on the market and in development. Processa is developing three Next Generation Chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Processa Pharmaceuticals, Inc.’s Item 2.02 8-K filed March 31, 2023; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.